| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
2,054 |
1,785 |
$11.01M |
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
1,687 |
1,534 |
$3.08M |
| J0739 |
Injection, cabotegravir, 1mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv) |
583 |
533 |
$2.03M |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
621 |
572 |
$1.13M |
| J0578 |
Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy |
192 |
181 |
$322K |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
218 |
169 |
$274K |
| J3490 |
Unclassified drugs |
93 |
42 |
$45K |
| M0201 |
Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home |
20 |
20 |
$70.00 |
| 0011A |
|
16 |
16 |
$0.00 |
| 0001A |
|
18 |
18 |
$0.00 |
| 0012A |
|
17 |
17 |
$0.00 |